This study will be a cluster-randomized, single-center trial comparing 0.9% saline (normal saline) vs physiologically-balanced crystalloid fluids (Lactated Ringers or Plasmalyte A) for intravenous fluid administration in the emergency department.
The administration of intravenous fluids is ubiquitous in the care of the acutely ill. Commonly available isotonic crystalloid solutions contain a broad spectrum of electrolyte compositions including a range chloride concentrations. Recent studies have associated solutions with supraphysiologic chloride content with hyperchloremia, metabolic acidosis and renal vasoconstriction, acute kidney injury and renal replacement therapy, and increased mortality but no large, randomized-controlled trials have been conducted. SaLt-ED will be a large, cluster-randomized trial enrolling adults requiring intravenous isotonic crystalloid administration and hospital admission from the Vanderbilt University Emergency Department from January 1st 2016 until April 30 2017. The primary endpoint will be hospital-free days to day 28.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
14,000
0.9% Saline will be used whenever an isotonic crystalloid is ordered
Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
Vanderbilt University Medical Center Adult Emergency Department
Nashville, Tennessee, United States
Hospital-free days to day 28
The number of days alive and free of hospitalization in the first 28 days after study enrollment. Patients alive at the time of discharge will be presumed to be alive at 28 days. A patient who dies before hospital discharge will receive zero hospital-free days. A patient who remains in the hospital 28 days after enrollment will receive zero hospital-free days.
Time frame: 28 days after enrollment
Stage II or greater KIDNEY DISEASE IMPROVING GLOBAL OUTCOMES (KDIGO) Acute Kidney Injury
Proportion of patients with Stage II or greater acute kidney injury by KDIGO creatinine criteria (defined as rise in serum creatinine level of at least 2-fold, a serum creatinine level greater than or equal to 4.0 mg/dL with an acute increase of at least 0.5 mg/dL, or initiation of new renal replacement therapy).
Time frame: 30 days after enrollment censored at hospital discharge
Major adverse kidney event by hospital discharge or day 30 (MAKE30)
At least one of: death, new renal replacement therapy, or persistent renal dysfunction at the time of hospital discharge (serum creatinine level ≥ 200% of baseline). Patients discharged prior to day 30 will be assumed not to develop this outcome between hospital discharge and day 30.
Time frame: 30 days after enrollment
In-Hospital Mortality
Death before hospital discharge
Time frame: 30 days or hospital discharge, whichever occurs first
Hospital length of stay
Duration of hospitalization
Time frame: Hospital length of stay assessed 90 days after enrollment
ICU-free days to day 28
Days alive and free of the intensive care unit in the first 28 days. Patients discharged prior to day 28 will be assumed to not have ICU days between discharge and day 28.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 28 days
Ventilator-free days to day 28
Days alive and free of mechanical ventilation in the first 28 days. Patients discharged prior to day 28 will be assumed to not have any ventilator days between discharge and day 28.
Time frame: 28 days
Vasopressor-free days
Days alive and free of vasopressor receipt in the first 28 days. Patients discharged prior to day 28 will be assumed to not have vasopressor days between discharge and day 28.
Time frame: 28 days
Receipt of new renal replacement therapy
Receipt of any form of renal replacement therapy in the first 30 days after enrollment in a patient who had not received renal replacement therapy prior to enrollment
Time frame: 30 days after enrollment or hospital discharge, whichever occurs first
Duration of new renal replacement therapy
Duration of renal replacement therapy in the first 30 days after enrollment in a patient who had not received renal replacement therapy prior to enrollment
Time frame: 30 days after enrollment
Peak creatinine
Highest creatinine in the 28 days after enrollment or hospital discharge, whichever occurs first
Time frame: 28 days after enrollment or hospital discharge, whichever occurs first
Change from baseline to peak creatinine
Change from baseline creatinine at enrollment to the highest creatinine before death or hospital discharge in the first 28 days
Time frame: 28 days after enrollment or hospital discharge, whichever occurs first
Incidence of metabolic acidosis and alkalosis
Incidence of metabolic acidosis and alkalosis in the first 30 days after enrollment as defined by bicarbonate values outside of the laboratory normal range.
Time frame: 30 days after enrollment or hospital discharge, whichever occurs first
Incidence of hyperchloremia and hypochloremia
Incidence of hyperchloremia and hypochloremia in the first 30 days after enrollment as defined by serum chloride values outside of the laboratory normal range.
Time frame: 30 days after enrollment or hospital discharge, whichever occurs first